Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
1(33%)
Results Posted
100%(1 trials)

Phase Distribution

Ph phase_3
1
33%
Ph phase_2
1
33%

Phase Distribution

0

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution2 total trials
Phase 2Efficacy & side effects
1(50.0%)
Phase 3Large-scale testing
1(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(1)
Other(1)

Detailed Status

Completed1
unknown1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 21 (50.0%)
Phase 31 (50.0%)

Trials by Status

completed133%
unknown133%
active_not_recruiting133%

Recent Activity

1 active trials
Showing 3 of 3
completedphase_2

Humacyte Acellular Tissue Engineered Vessel (ATEV) in Patients With Vascular Trauma

NCT03005418
active_not_recruitingphase_3

To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis

NCT05908084
unknown

Individual Patient Expanded Access for Acellular Tissue Engineered Vessel (ATEV) for Vascular Disease and Dialysis Access

NCT07141641

Clinical Trials (3)

Showing 3 of 3 trials
NCT03005418Phase 2

Humacyte Acellular Tissue Engineered Vessel (ATEV) in Patients With Vascular Trauma

Completed
NCT05908084Phase 3

To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis

Active Not Recruiting
NCT07141641

Individual Patient Expanded Access for Acellular Tissue Engineered Vessel (ATEV) for Vascular Disease and Dialysis Access

Unknown

All 3 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
3